According to Zacks, “China Biologic Products, Inc., through its indirect majority-owned subsidiary, is principally engaged in the research, development, production, manufacturing and sale of plasma-based biopharmaceutical products to hospitals and other health care facilities in China. Its subsidiary, Shandong Taibang Biological Products Co. Ltd., operates from its manufacturing facility located in Taian City, Shandong Province. The Company’s principal products include its approved human albumin and immunoglobulin products. These human albumin products are mainly used to increase blood volume and its immunoglobulin products are used for the treatment and prevention of diseases. “
Several other analysts have also recently issued reports on the stock. BidaskClub cut shares of China Biologic Products from a strong-buy rating to a buy rating in a research note on Thursday, May 9th. Jefferies Financial Group cut shares of China Biologic Products from a hold rating to an underperform rating and dropped their price objective for the company from $67.00 to $62.00 in a research note on Monday, March 11th. Credit Suisse Group set a $88.00 price objective on shares of China Biologic Products and gave the company a hold rating in a research note on Friday, March 8th. Finally, ValuEngine raised shares of China Biologic Products from a hold rating to a buy rating in a research note on Friday, March 1st. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the stock. China Biologic Products presently has a consensus rating of Hold and an average price target of $78.00.
China Biologic Products (NASDAQ:CBPO) last announced its quarterly earnings data on Friday, May 10th. The biopharmaceutical company reported $1.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.99 by $0.12. China Biologic Products had a net margin of 27.71% and a return on equity of 8.81%. The company had revenue of $129.78 million during the quarter, compared to analysts’ expectations of $119.50 million. During the same quarter in the prior year, the company earned $1.21 EPS. As a group, equities analysts expect that China Biologic Products will post 3.78 earnings per share for the current year.
Several institutional investors have recently bought and sold shares of CBPO. AdvisorNet Financial Inc purchased a new stake in shares of China Biologic Products in the 4th quarter valued at approximately $57,000. Cutler Group LP grew its stake in shares of China Biologic Products by 58.4% in the 4th quarter. Cutler Group LP now owns 1,356 shares of the biopharmaceutical company’s stock valued at $102,000 after buying an additional 500 shares during the period. Amundi Pioneer Asset Management Inc. grew its stake in shares of China Biologic Products by 79.9% in the 4th quarter. Amundi Pioneer Asset Management Inc. now owns 2,100 shares of the biopharmaceutical company’s stock valued at $159,000 after buying an additional 933 shares during the period. Legal & General Group Plc grew its stake in shares of China Biologic Products by 25.2% in the 3rd quarter. Legal & General Group Plc now owns 2,357 shares of the biopharmaceutical company’s stock valued at $189,000 after buying an additional 475 shares during the period. Finally, Quantamental Technologies LLC purchased a new stake in shares of China Biologic Products in the 1st quarter valued at approximately $308,000. 37.31% of the stock is owned by institutional investors and hedge funds.
About China Biologic Products
China Biologic Products Holdings, Inc engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia.
Featured Story: What Does a Sell-Side Analyst Rating Mean?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.